Scopio Labs Competitive Intelligence & Landscape

Scopio Labs (scopiolabs.com) is a pioneering company revolutionizing first-line diagnostic testing in hematology through its innovative Full-Field Digital Cell Morphology imaging and analysis platforms [https://scopiolabs.com/]. Founded by two physicists, the company's vision is to change the standard of healthcare by harnessing computational photography and AI to image and analyze cell morphology at an unprecedented scale, ultimately expediting access to life-saving treatments and improving patient outcomes [https://scopiolabs.com/about/].

Scopio Labs offers a scalable technology platform and a suite of applications designed to bring hematology into the digital era, addressing urgent lab problems such as rising workloads, staff shortages, and subjective results by enabling fully autonomous analysis of thousands of blood cells [https://scopiolabs.com/].

The core products and services provided by Scopio Labs include its Full-Field Peripheral Blood Smear Application, which is CE-marked and FDA-cleared and commercially available in the U.S., UK, Europe, and other territories [https://scopiolabs.com/]. They also offer the Full-Field Bone Marrow Aspirate Application, which is CE-marked and cleared for sales in various regions, though not yet commercially available in the US for in vitro diagnostic procedures [https://scopiolabs.com/]. The company is also developing Complete Blood Morphology (CBM), which is currently under development and not available for in vitro diagnostic use [https://scopiolabs.com/]. These platforms deliver dynamic digital images at 100x resolution, AI-powered cell morphology, and true remote access for consultation and collaboration, leading to 60% faster turnaround times for peripheral blood smear reviews [https://scopiolabs.com/contact/].

Scopio Labs serves the global hematology and pathology market, partnering with laboratories of all sizes to drive innovation and enhance patient care [https://scopiolabs.com/]. Their solutions aim to replace traditional light microscopy, enable full digitization of diagnostic processes, and standardize morphology results across healthcare systems. The company has dual headquarters in Parsippany, New Jersey, and Tel Aviv, Israel [https://scopiolabs.com/news/scopio-labs-secures-42-million-in-funding-led-by-fortissimo-capital/].

Scopio Labs has successfully secured significant funding rounds, including a $50 million investment in 2022 and a $42 million Series D funding round led by Fortissimo Capital in July 2024, demonstrating strong investor confidence in its groundbreaking technology and market potential [https://scopiolabs.com/news/scopio-raises-50m-to-take-a-deeper-look-into-our-blood-cells/].

Scopio Labs (scopiolabs.com) offers revolutionary Full-Field™ imaging platforms and AI-powered diagnostic applications designed to digitize and enhance hematology lab workflows. Their core offerings include the Scopio X100 and Scopio X100HT imaging systems, which utilize advanced computational photography to provide 100x resolution full-field digital images of blood samples. These platforms aim to completely replace manual microscopy, enabling remote access, consultation, and collaboration for lab professionals globally. The technology focuses on addressing critical lab challenges such as rising workloads, staff shortages, and inter- and intra-user variability in manual analysis.

Scopio Labs provides specialized applications built on its Full-Field™ technology. The Full-Field Peripheral Blood Smear (FF-PBS) Application is a flagship product, available on both the X100 and X100HT platforms. This application is an end-to-end digital cell morphology solution that includes an AI-powered Decision Support System (DSS) for efficient WBC differentials, RBC morphology evaluation, and platelet estimations https://scopiolabs.com/peripheral-blood-smear/. The FF-PBS is FDA cleared and CE marked, and is commercially available in the U.S., UK, Europe, and other territories https://scopiolabs.com/. The company also offers the Full-Field Bone Marrow Aspirate (FF-BMA) Application, which is CE-marked and cleared for sales in additional regions, though not yet commercially available in the US for in vitro diagnostic procedures https://scopiolabs.com/ff-bma/.

While specific pricing plans, tiers, or recent pricing changes are not explicitly detailed on the public-facing areas of the Scopio Labs website or in the provided sources, the company emphasizes the transformative value of its solutions. The Scopio X100 is described as the first fully digital platform for small and medium labs, capable of processing 15 slides/hour for 200 WBC diffs https://scopiolabs.com/imaging-platforms/. The AI integration is a key feature across their applications, leveraging machine learning to analyze vast numbers of cells and provide decision support, thereby improving diagnostic speed and accuracy beyond human capabilities https://scopiolabs.com/ai/. The company's focus is on providing a comprehensive digital solution that enhances efficiency and standardization in hematology labs, ultimately leading to improved patient care.

Scopio Labs is a rapidly growing medical technology company focused on revolutionizing hematology and cell morphology analysis to improve patient outcomes. Their innovative Full-Field™ imaging platforms and AI-powered products aim to address critical challenges in laboratories, such as rising workloads, staff shortages, and the need for standardized results. The company's vision involves leveraging computational photography and AI to image and analyze cell morphology at an unprecedented scale, thus expediting access to life-saving treatments. Their Peripheral Blood Smear Application is already CE-marked and FDA-cleared, with commercial availability in the U.S., UK, Europe, and other territories, while their Bone Marrow Aspirate Application is also CE-marked and cleared for sales in additional regions [https://scopiolabs.com/].

Regarding hiring trends, Scopio Labs frequently posts various job openings that reflect its strategic expansion and technological focus. Historically, roles such as Presale Engineer in the United States, Clinical Solutions Consultant- UK, and Clinical Affairs Team Lead in Tel Aviv have been advertised [https://scopiolabs.com/careers/co/united-states/5C.86E/presale-engineer/all/], [https://scopiolabs.com/careers/co/uk/15.F52/clinical-solutions-consultant-uk/all/], [https://scopiolabs.com/careers/co/product/70.054/clinical-affairs-team-lead/all/]. These positions highlight Scopio Labs' commitment to expanding its market reach, strengthening its clinical presence, and developing its cutting-edge AI-driven solutions. The company's job descriptions emphasize its mission to facilitate quicker and earlier detection and diagnosis of blood-related diseases through its transformative technology [https://scopiolabs.com/digital-cell-morphology/could-digital-imaging-technology-improve-critical-staff-shortages-in-hematology-laboratories/].

While specific details on layoffs are not publicly available through the provided sources, Scopio Labs' career page has, at times, indicated no open positions, stating, "We don't have any open positions at this time. Please visit again soon" [https://scopiolabs.com/careers/]. This suggests that while recruitment is active when specific roles are needed, there might be periods of consolidation. The company's hiring patterns signal a strategic focus on expanding its commercial footprint in key regions like the US and UK, and strengthening its product development and clinical support teams, particularly in areas related to digital cell morphology and AI-powered diagnostics. This aligns with their goal of addressing urgent problems in hematology laboratories, such as staff shortages and the demand for more efficient, digital workflows [https://scopiolabs.com/].

Scopio Labs, a pioneer in Full-Field Digital Cell Morphology imaging and analysis platforms, has demonstrated robust financial growth through significant fundraising efforts. The company successfully completed a Series D funding round, securing $42 million on July 24, 2024, led by Fortissimo Capital with participation from existing investors [Source: https://scopiolabs.com/news/scopio-labs-secures-42-million-in-funding-led-by-fortissimo-capital/]. This substantial investment underscores confidence in Scopio Labs' innovative technology and its potential to revolutionize hematology diagnostics. The company's platforms, including the Full-Field Peripheral Blood Smear Application (CE-marked and FDA-cleared) and the Full-Field Bone Marrow Aspirate Application (CE-marked), are already commercially available in various regions, indicating a strong market presence and revenue streams [Source: https://scopiolabs.com/].

Prior to its Series D, Scopio Labs raised $50 million in a Series C round on February 9, 2022, as reported by multiple sources including its own news releases [Source: https://scopiolabs.com/news/scopio-raises-50m-to-take-a-deeper-look-into-our-blood-cells/], [Source: https://scopiolabs.com/news/digital-blood-test-co-scopio-labs-raises-50m/], [Source: https://scopiolabs.com/news/scopio-aims-to-turn-hematology-into-remote-work-with-50m-c-round/]. This funding further propelled its mission to digitize and quantify blood cell morphology. The company also secured a $16 million Series B round on April 28, 2020, bringing its total funding at that time to $30 million [Source: https://scopiolabs.com/news/scopio-labs-closes-16m-series-b-round-to-expand-commercial-rollout-of-automated-microscopy-solutions/]. These successive funding rounds highlight Scopio Labs' consistent ability to attract significant capital, reinforcing its financial health and growth trajectory.

Scopio Labs was founded in 2015 and has since focused on developing breakthroughs in digital microscopy [Source: https://scopiolabs.com/news/scopio-labs-launches-full-field-peripheral-blood-smear-application-bringing-end-to-end-digital-workflow-to-hematology-labs-to-transform-diagnostic-testing/]. The company's strategic hires, such as the Chief Business Development Officer in 2023, demonstrate a clear focus on accelerating market penetration and growth for its laboratory diagnostic solutions [Source: https://scopiolabs.com/news/scopio-labs-doubles-down-on-digital-cell-morphology-go-to-market-strategy-in-2023/]. While specific revenue figures are not publicly disclosed, the continuous investment and expansion of its commercially available products, combined with its strong market partnerships with global hematology leaders, suggest a healthy financial outlook and a robust strategy for capturing a significant share of the digital pathology market [Source: https://scopiolabs.com/]. The company's focus on computational photography and AI positions it at the forefront of innovation in diagnostic testing [Source: https://scopiolabs.com/about/].

Scopio Labs actively engages with the hematology and pathology communities by participating in numerous global events, including prominent conferences, trade shows, and specialized workshops. This involvement allows them to showcase their Full-Field digital morphology platforms and foster critical discussions on the future of laboratory diagnostics. Their future schedule includes significant appearances at BDL 2026 in Berlin, Germany (May 21-22), Biomed-J 2026 in Paris, France (May 28-29), ADLM 2026 in Anaheim, CA, US (July 28-30), EH4AP 2026 in Berlin, Germany (October 3-6), and DGHO 2026 in Vienna, Austria (October 9-12), where attendees can book one-on-one meetings to learn more about their innovations [scopiolabs.com/events/].

Scopio Labs also regularly attends and contributes to key industry events. In 2024, they were present at the Society of Hematologic Oncology (SOHO) [scopiolabs.com/company/join-scopio-labs-at-society-of-hematologic-oncology-soho-2024/] and the Italian and European Congress of Pathology (ECP) [scopiolabs.com/company/meet-scopio-labs-at-italian-and-european-congress-of-pathology-ecp-2024/], highlighting their commitment to staying at the forefront of technological and research advancements in pathology. Their participation at BSH 2024 provided insights into transforming hematology practices [scopiolabs.com/company/bsh-2024-five-key-takeaways-transforming-haematology/]. Earlier, in October 2022, Scopio's Chief Product Officer, Dr. Amy Meitus, co-conducted a workshop at the DPA Pathvisions Conference, discussing the benefits of digital bone marrow analysis and its impact on workflow efficiency and collaboration [scopiolabs.com/digital-pathology/bringing-digital-pathology-to-more-ologies-will-drive-holistic-patient-care/].

Beyond physical events, Scopio Labs maintains a robust online presence through its Resource Center, which features webinars and white papers. One notable resource is the "2026 Hematology Laboratory Survey: The State of Blood Sample Review," a white paper published on January 19, 2026, summarizing insights from 220 laboratory professionals [scopiolabs.com/resources/]. Through these diverse engagements, Scopio Labs not only showcases its cutting-edge AI-powered digital imaging for blood and bone marrow analysis but also fosters education and collaboration within the global hematology and pathology communities.